Core Viewpoint - China Resources Medical (01515.HK) anticipates a decline in profit attributable to shareholders by approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024. After excluding a one-time management fee and compensation of approximately RMB 210 million from the YanHua IOT agreement, the profit is expected to decrease by about 55% to 60% compared to 2024 [1] Group 1 - The expected profit decline is primarily due to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the Investment-Operation-Transfer (IOT) business model, resulting in a corresponding decline in profit contribution [1] - In the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operating costs, and increase operational efficiency [1]

Core Viewpoint - China Resources Medical (01515) anticipates a decline in profit attributable to shareholders for the six months ending June 30, 2025, by approximately 20% to 25% compared to the same period in 2024, with a more significant drop of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement totaling approximately RMB 210 million [1] Financial Performance - The expected profit decline is primarily due to a decrease in average medical expenses under the healthcare insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a corresponding decrease in profit contribution from this segment [1] Future Outlook - In the second half of 2025, the company plans to actively improve its revenue structure, promote refined management, control operating costs, and enhance operational efficiency [1]